U.S. stocks closed a shortened week with broad losses as markets observed Good Friday. Major large-cap losers included Nike (down 14.29% after missing Q4 guidance), Boston Scientific (down 9.32% following clinical trial data and analyst downgrade), and Sysco (down 13.56% after announcing Jetro acquisition and analyst downgrades). Other significant decliners included Texas Pacific Land, Venture Global, EQT, Rogers Communications, Kratos Defense, and Antero Resources.

Q1 2026 marked a dramatic market shift with oil surging 84% while Bitcoin plummeted 23%, signaling a rotation away from mega-cap growth toward real assets and energy. AI infrastructure plays like SanDisk and Lumentum soared on strong demand, while richly valued software and speculative growth stocks faced significant de-rating. The quarter demonstrated that traditional hedges and narratives are no longer reliable, with cash flow and tangible assets becoming increasingly important.

Despite broad market weakness with the S&P 500 down 2% YTD amid geopolitical tensions, three stocks are significantly outperforming: SanDisk (up 8.10% YTD, benefiting from NAND flash shortage and AI demand), Texas Pacific Land (up 80% YTD, driven by AI data center partnerships), and an unnamed healthcare stock (up over 80% YTD, transitioning beyond COVID focus). Each operates in different sectors, demonstrating selective strength amid market selloff.

Texas Pacific Land Corporation (TPL) stock rose 0.6% on February 23, 2026, outperforming the broader market decline. KeyBanc analyst Tim Rezvan raised his price target from $350 to $639 per share, citing the company's significant opportunity to develop power generation and data center facilities on its vast Permian Basin land holdings. The analyst believes TPL is well-positioned to capitalize on the booming AI-driven data center industry while maintaining its traditional energy sector revenue.

Ten large-cap stocks were top performers last week, with First Majestic Silver leading gains at 25.23% following better-than-expected Q4 results. Other notable gainers include Moderna (19.68%) on FDA seasonal flu vaccine review news, Global Payments (19.52%) with strong Q4 earnings and a $2.6B buyback authorization, and Coinbase (11.32%). Companies like Omnicom, Garmin, Figma, and Pan American Silver also reported strong quarterly results and positive guidance.

Ten large-cap stocks were top performers during the week of February 9-13, 2026. Magna International led with a 26.81% gain following better-than-expected Q4 results and raised FY26 guidance. Other notable gainers included Generac Holdings (22.25%), Rivian Automotive (20.20%), BorgWarner (20.15%), and Akamai Technologies (17.64%), all driven by strong earnings reports and analyst upgrades.

Oil prices surged following President Trump's escalatory rhetoric toward Iran, with WTI crude rising to nearly $63/barrel and Brent crude reaching $68/barrel. Geopolitical tensions over the Strait of Hormuz, combined with U.S. supply disruptions from winter weather and a weaker dollar, drove the rally. Energy stocks significantly outperformed, with the XLE ETF up 11% this month, marking the sector's best performance since late 2022.

Texas Pacific Land Corporation will list some of its equity on the newly formed NYSE Texas exchange, maintaining its primary listing on the main NYSE. The move is seen as a symbolic development that could raise the company's profile in Texas.

Texas Pacific Land Corp experienced a stock decline despite steady Q2 results, with water sales dropping 34% due to reduced operator activity, though the CFO expects recovery in the second half of the year.

Palantir's stock has surged 109% year-to-date, driven by its AI platform and government contracts, but its extremely high price-to-sales ratio of 126 suggests potential overvaluation and risk of a significant stock price correction.

Palantir Technologies has seen a massive 2,100% stock gain since 2023, driven by AI demand. While a Wedbush analyst predicts it could become a trillion-dollar company in three years, the stock is currently extremely overvalued with significant downside risk.

Several large-cap stocks, including PDD Holdings, Regeneron Pharmaceuticals, and Burlington Stores, were among the top losers last week, with declines ranging from 11.9% to 29.3%. The reasons for the losses varied, from mixed clinical trial results to earnings misses and tariff concerns.